All Policies Include Coronavirus Cover

Coronavirus FAQs

Questions about cover for coronavirus? Read our FAQs and find out what our policies can do for you. If you would like to contact us, please note we are currently only available 09:00 to 17:30 Monday to Friday due to reduced operational capacity. Thank you.

Diabetes care 'should be personalised by gender'

06 August 2018 08:04

Diabetes treatment should be more tailored

Diabetes treatment should be more tailored

Simple factors such as gender and body mass can help doctors to personalise care for patients with type 2 diabetes and avoid harmful side effects, according to a study.

Clinicians can match the right drug to patients by taking into account BMI and sex, which can improve blood sugar control and avoid side-effects, such as weight gain and hypoglycaemia.

No additional cost

Researchers at the University of Exeter said the findings would come at no additional cost to the NHS.

Metformin is the first-line of drug treatment in type 2 diabetes but many patients will eventually need additional drugs on top of metformin to lower their blood sugar levels.

Currently, clinicians have to make prescribing decisions on these additional drug options based on limited available guidance.

Recent research involving the Exeter team has revealed there is great regional variation across the UK in the prescribing of these additional drugs.

The new study provided a starting point for a more evidence-based approach to the prescribing of drugs after metformin.

Based on a patients' gender and BMI, they found important differences in the likely success of the commonly-prescribed drugs sulfonylureas and thiazolidinediones in lowering blood sugar levels, and in the risk of common side effects.

For example, obese females were far more likely to have good blood glucose control on thiazolidinediones than sulfonylureas, whilst non-obese males had the opposite result, they were far more likely to have good blood glucose control on sulfonylureas than thiazolidinediones.

The Exeter team used anonymous data from more than 29,000 patients who had either taken part in trials or were treated in UK GP practices.

By combining these datasets, the researchers were able to show their findings are robust and potentially applicable to many of the 3.5 million-plus people currently diagnosed with type 2 diabetes in the UK.

Precision medication

PhD student John Dennis, who led the study, said: "Our findings are important as they provide the first evidence that personalised or 'precision' medicine approaches in diabetes can be based on simple patient characteristics available to any doctor, rather than expensive genetics or other technology.

"This simple personalised approach could be implemented immediately within the NHS without any additional cost."

The study, Sex And BMI Alter The Benefits And Risks Of Sulfonylureas And Thiazolidinediones In Type 2 Diabetes: A Framework For Evaluating Stratification Using Routine Clinical And Individual Trial Data, is published in journal Diabetes Care.

At World First we're happy to offer great value, tailored travel insurance whether you have type 1 or type 2 diabetes.